Impact of Frailty on the Outcomes of Patients with Pancreatic Cancer Undergoing Neoadjuvant Therapy
Einfluss von Frailty auf die Ergebnisse von Patient:innen mit Pankreaskarzinom unter neoadjuvanter Therapie
Cancers · 18.12.2025 · 17 (24) · 4030
DOI: 10.3390/cancers17244030 ↗Auf einen Blick
Bei 252 Patient:innen mit lokalisiertem PDAC war Frailty nach mFI-11 mit geringerer Resektionswahrscheinlichkeit und schlechterem Gesamtüberleben verbunden.
Fragestellung
Welchen Einfluss hat eine Frailty zu Behandlungsbeginn auf die Ergebnisse von Patient:innen mit PDAC unter neoadjuvanter Therapie?
Methode
Retrospektive Einzelzentrumsstudie im Intention-to-treat-Design; 2019–2025; Analyse von mFI-11 und funktioneller Frailty in einem Subset.
Ergebnisse
252 Patient:innen; 62,7 % wurden nach median 3,6 Monaten NT reseziert. Frailty war mit geringerer Resektion assoziiert (OR 0,09; 95 %-KI 0,02–0,44) und mit schlechterem OS (HR 3,00; 95 %-KI 1,46–6,20).
Schlussfolgerung der Autor:innen
Bei Patient:innen mit lokalisiertem PDAC unter NT war Frailty nach mFI-11 mit geringerer Resektionswahrscheinlichkeit und schlechterem Gesamtüberleben assoziiert.
Kernaussagen
- Frailty nach mFI-11: geringere Chance auf Resektion
- Frailty: schlechteres Gesamtüberleben (HR 3,00)
- Im Subset war nur abnormale Haltung mit Resektion assoziiert
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 18.12.2025. Verfasst von Nicholas R Williams und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Ohio State University College of Medicine Bennett Medical Student Research Scholarship, Ohio State University College.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Background
Neoadjuvant therapy (NT) is increasingly utilized for patients with localized pancreatic ductal adenocarcinoma (PDAC). Toxicities during NT are common, often leading to the inability to undergo surgical resection, yet risk factors for attrition are poorly understood. Therefore, we sought to evaluate the impact of baseline frailty on outcomes of patients with PDAC undergoing NT.
Methods
All patients with potentially resectable (PR) or borderline resectable (BR) PDAC who initiated neoadjuvant chemotherapy and/or chemoradiation between 2019 and 2025 at a single institution were assessed retrospectively in an intention-to-treat fashion. The association between frailty as defined by the modified 11-item frailty index (mFI-11) and receipt of surgical resection as well as other secondary endpoints was assessed. Comprehensive functional frailty assessments were prospectively obtained in a subset of patients.
Results
Among 252 eligible patients, the median age was 67 years, 56.7% were male, 90.9% were White, 49.6% had PR disease, and 5.2% were frail according to mFI-11. After a median 3.6 months of NT, 62.7% underwent surgical resection. Frail individuals had worse performance status and increased comorbidities compared with non-frail patients. On multivariable analysis, male sex, BR anatomic staging, initial use of Gemcitabine + nab-paclitaxel, and frailty (OR 0.09; 95%CI 0.02–0.44) were associated with reduced odds of undergoing resection. Along with increased baseline CA 19-9 levels, frailty was independently associated with worse overall survival (HR 3.00; 95%CI 1.46–6.20). Among 39 patients who underwent formal functional frailty assessment, only abnormal posture was associated with lower odds of surgical resection following NT (OR, 0.22; 95% CI, 0.05–0.92), and no aspects of functional frailty were associated with overall survival.
Conclusions
Among patients with localized PDAC initiating NT, frailty as assessed by mFI-11 was associated with reduced odds of undergoing surgical resection and worse overall survival. Future research should focus on efforts to improve functional status during NT.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
ORCID-Profile: Nicholas R Williams, Amanda K Walsh, Timothy M Pawlik, Jordan M Cloyd
Förderung
- The Ohio State University College of Medicine Bennett Medical Student Research Scholarship
- Ohio State University College
Zitieren
APA
Williams, N. R., Leuschner, T., Walsh, A. K., Gault, K., Ingram, A., Blair, A. B., Tsai, S., Pawlik, T. M., Dillhoff, M. E., & Cloyd, J. M. (2025). Impact of Frailty on the Outcomes of Patients with Pancreatic Cancer Undergoing Neoadjuvant Therapy. Cancers, 17(24), 4030. https://doi.org/10.3390/cancers17244030
Vancouver
Williams NR, Leuschner T, Walsh AK, Gault K, Ingram A, Blair AB, et al. Impact of Frailty on the Outcomes of Patients with Pancreatic Cancer Undergoing Neoadjuvant Therapy. Cancers. 2025;17(24):4030. doi:10.3390/cancers17244030
BibTeX
@article{Williams2025,
author = {Williams, Nicholas R and Leuschner, Thomas and Walsh, Amanda K and Gault, Kayla and Ingram, Amber and Blair, Alex B and Tsai, Susan and Pawlik, Timothy M and Dillhoff, Mary E and Cloyd, Jordan M},
title = {Impact of Frailty on the Outcomes of Patients with Pancreatic Cancer Undergoing Neoadjuvant Therapy},
journal = {Cancers},
year = {2025},
volume = {17},
number = {24},
pages = {4030},
doi = {10.3390/cancers17244030}
}
EUVIMED